Peptide Therapeutics in Oncology: Proteasome Inhibitors, HDAC Inhibitors, and Beyond

Oncology drug development is dominated by three modalities: small molecules, monoclonal antibodies, and increasingly, cell and gene therapies. Peptides occupy a narrow but important band between small molecules and antibodies. They can be manufactured by solid-phase synthesis rather than mammalian cell culture, penetrate solid tumors more readily than 150 kDa antibodies, and can be engineered to bind targets that are difficult to drug with small molecules — for example, protein-protein interaction surfaces and receptor allosteric sites.

The trade-offs are well known: rapid proteolytic degradation, renal clearance, limited oral bioavailability, and sometimes immunogenicity. Modern oncology peptide design addresses these through cyclization (romidepsin is a bicyclic depsipeptide), N-methylation, unnatural amino acids, and covalent warheads (carfilzomib's epoxyketone, bortezomib's boronate) that lock the drug to its target.

Approved oncology peptides fall into roughly four mechanistic categories: proteasome inhibitors (bortezomib, carfilzomib, ixazomib), HDAC inhibitors (romidepsin), hormone-axis modulators (GnRH agonists for prostate and breast cancer; somatostatin analogs for neuroendocrine tumors), and peptide-radioligand conjugates (lutetium-177 DOTATATE). The experimental pipeline adds cell-penetrating peptides, peptide-drug conjugates, and MHC-targeted tumor-associated peptide vaccines.

The ubiquitin-proteasome system is the primary route by which eukaryotic cells degrade regulatory proteins. Multiple myeloma plasma cells produce immunoglobulin at enormous rates and are unusually dependent on proteasome function to clear misfolded proteins; this vulnerability made the proteasome a therapeutic target, and peptide-derived inhibitors reshaped myeloma treatment over the 2003–2015 decade.

Bortezomib (Velcade, PS-341) is a dipeptide boronate that reversibly binds the chymotrypsin-like active site of the 20S proteasome. FDA-approved in 2003 for relapsed multiple myeloma and later expanded to mantle cell lymphoma and frontline myeloma, bortezomib is typically dosed twice weekly by subcutaneous or intravenous injection. Peripheral neuropathy is the dose-limiting toxicity; the subcutaneous route reduces neuropathy incidence relative to IV dosing.

Carfilzomib (Kyprolis, PR-171) is an epoxyketone tetrapeptide that binds the proteasome irreversibly. FDA-approved in 2012 for relapsed/refractory multiple myeloma, carfilzomib produces deeper proteasome inhibition than bortezomib and is associated with less peripheral neuropathy, but carries a boxed warning for cardiovascular toxicity including heart failure and cardiac arrest. The oral proteasome inhibitor ixazomib (Ninlaro, citrate) completes the class.

For head-to-head detail, see the companion bortezomib vs carfilzomib comparison. These drugs are not used outside their approved indications — they are hematologist-prescribed cytotoxic agents with specific monitoring requirements.

Histone deacetylase (HDAC) inhibitors reactivate silenced tumor suppressor genes by preserving histone acetylation marks, shifting chromatin toward a transcriptionally open state. The class is heterogeneous, but among FDA-approved HDAC inhibitors, romidepsin (Istodax, FK228) is the one genuine peptide — a bicyclic depsipeptide natural product isolated from Chromobacterium violaceum.

Romidepsin gained FDA accelerated approval in 2009 for cutaneous T-cell lymphoma (CTCL) and in 2011 for peripheral T-cell lymphoma (PTCL), though the PTCL indication was voluntarily withdrawn in 2021 following confirmatory trial results. The drug is a prodrug: after intravenous infusion, intracellular glutathione reduces a disulfide bond, unmasking a zinc-binding thiol that chelates the catalytic zinc of Class I HDACs (HDAC1 and HDAC2 preferentially).

Romidepsin is administered as a 4-hour IV infusion on days 1, 8, and 15 of 28-day cycles. Adverse events include nausea, thrombocytopenia, neutropenia, fatigue, and QT-interval prolongation — the cardiovascular signal is clinically meaningful and requires baseline and on-treatment ECG monitoring. Despite its narrow approved indication and challenging toxicity profile, romidepsin remains an important option for CTCL patients who have failed multiple prior therapies.

Somatostatin is a 14- or 28-amino-acid inhibitory hormone that suppresses secretion across the GI tract, pancreas, and pituitary. Its short plasma half-life (~2 minutes) makes it impractical as a drug, but synthetic analogs with stabilized structures have been the mainstay of neuroendocrine tumor (NET) management for three decades.

Octreotide (Sandostatin) is the first-generation somatostatin analog, an 8-amino-acid cyclic peptide binding preferentially to SSTR2 and SSTR5. Approved for carcinoid syndrome, VIPoma, and acromegaly, octreotide is available as a short-acting subcutaneous formulation and a long-acting release depot (Sandostatin LAR) dosed monthly. Lanreotide (Somatuline Depot) is a structurally similar SSTR2/5-selective analog delivered as a prefilled deep subcutaneous injection. Pasireotide (Signifor) is a broader-spectrum multi-SSTR agonist with affinity for SSTR1, 2, 3, and 5, approved for Cushing's disease and acromegaly refractory to other analogs.

In NETs, somatostatin analogs control carcinoid-syndrome symptoms (flushing, diarrhea) via SSTR2 inhibition of hormone secretion and slow tumor progression independently of symptom control, as shown in the PROMID and CLARINET trials. The evolution of the class continues through somatostatin-receptor-targeted radioligand therapy — lutetium-177 DOTATATE (Lutathera) couples a somatostatin analog to a beta-emitting radionuclide for midgut NETs. See the dedicated somatostatin-analogs guide and octreotide vs lanreotide vs pasireotide comparison for detailed treatment-selection considerations.

Gonadotropin-releasing hormone (GnRH) agonists exploit a paradoxical pharmacology: continuous exposure to a GnRH agonist initially stimulates the pituitary to release LH and FSH, then desensitizes and downregulates GnRH receptors, causing medical castration. For hormone-sensitive prostate cancer and some premenopausal hormone-receptor-positive breast cancers, eliminating testicular or ovarian steroid output slows tumor growth.

Leuprolide (Lupron, Eligard) is the archetypal GnRH agonist — a 9-amino-acid peptide dosed as a monthly, 3-monthly, 4-monthly, or 6-monthly depot. FDA-approved in 1985 for prostate cancer, leuprolide became the dominant androgen-deprivation therapy for advanced prostate cancer. Expansions include breast cancer (in combination with tamoxifen or an aromatase inhibitor in premenopausal women), endometriosis, uterine fibroids, and central precocious puberty.

The 'testosterone flare' in the first 1–2 weeks of leuprolide therapy can transiently worsen prostate cancer symptoms, which is why GnRH antagonists (degarelix, relugolix) are preferred in metastatic disease with symptomatic bone involvement. Related GnRH agonists include goserelin (Zoladex), histrelin (Vantas, a 12-month implant), and triptorelin. In breast cancer, leuprolide and goserelin are used with tamoxifen or aromatase inhibitors in the SOFT and TEXT trials' treatment paradigms for premenopausal women with intermediate-to-high-risk ER-positive disease.

Cell-penetrating peptides (CPPs) are short (5–30 residue) cationic or amphipathic peptides that cross the plasma membrane and deliver cargoes — proteins, nucleic acids, or small molecules — into the cytoplasm. The class includes TAT (from HIV-1 Tat protein), penetratin (from Drosophila Antennapedia), and synthetic polyarginine sequences. In oncology research, CPPs have been used primarily as delivery vehicles for intracellular targets that are otherwise undruggable with biologics.

PTD-DBM is a research-stage CPP-conjugate designed to disrupt Wnt/β-catenin signaling — a pathway aberrantly activated in colorectal cancer, hepatocellular carcinoma, and several other tumors, but historically difficult to drug because β-catenin is an intracellular scaffolding protein without a conventional active site. PTD-DBM fuses a protein-transduction-domain (PTD) sequence to a CXXC domain of the Dishevelled-binding motif, disrupting the interaction between CXXC5 and Dishevelled and thereby reducing downstream Wnt-driven transcription. Preclinical models have shown activity in colorectal cancer and alopecia; no human clinical oncology data is available at this writing.

Other CPP-conjugate programs in early clinical development include tumor-homing RGD- and iRGD-based delivery systems, proteomimetic stapled peptides targeting MCL-1 and p53-MDM2, and peptide vaccines displaying tumor-associated neoantigens. The CPP field is methodologically mature but therapeutically still mostly preclinical in oncology.

Peptide-drug conjugates (PDCs) apply the antibody-drug-conjugate logic — tumor-targeted delivery of a cytotoxic warhead — with a peptide replacing the antibody. Peptides offer faster tumor penetration, renal (rather than hepatic) clearance, and lower manufacturing cost. The first approved PDC is melphalan flufenamide (Pepaxto), though it was withdrawn from the US market in 2021 after a confirmatory trial failed to show overall survival benefit, underscoring the developmental challenges of the class.

Peptide radioligand therapy is the more clinically successful extension of this concept. Lutetium-177 DOTATATE (Lutathera) conjugates a somatostatin-analog targeting motif to a chelator bearing a beta-emitting lutetium-177 radionuclide; tumor-expressed SSTR2 internalizes the conjugate and the radiation kills the neuroendocrine tumor cell. Lutetium-177 PSMA-617 (Pluvicto, FDA-approved 2022) applies the same logic to prostate-specific membrane antigen in metastatic castration-resistant prostate cancer. Theranostic pairings with gallium-68 or copper-64 imaging tracers allow patient selection based on target expression.

Beyond approved agents, peptide-targeted alpha emitters (actinium-225, thorium-227) are in late-stage clinical trials, and receptor-targeted PDCs for melanoma (MC1R), breast cancer (GRPR, bombesin receptors), and lung cancer are in earlier development. The peptide-radioligand category is likely the fastest-growing oncology peptide modality through the late 2020s.

Several structural limits keep oncology peptides from the dominance that antibodies and small molecules enjoy. Plasma half-lives are short — bortezomib's half-life is under an hour, though its tissue binding extends effective proteasome inhibition. Renal clearance means many peptides require dose adjustment in renal impairment. Oral bioavailability is generally poor, so most oncology peptides are administered parenterally, which creates adherence and access challenges.

Resistance is a recurring issue. Bortezomib resistance emerges via proteasome subunit mutations, drug efflux upregulation, and rewired protein-quality-control pathways. Somatostatin-analog resistance in NETs involves SSTR2 downregulation and tachyphylaxis. HDAC inhibitors trigger compensatory upregulation of alternative epigenetic pathways. Combination regimens (bortezomib with dexamethasone, romidepsin with pralatrexate, somatostatin analogs with everolimus) partially address resistance but introduce additive toxicity.

Manufacturing and cost are non-trivial. Bortezomib and carfilzomib require precision solid-phase synthesis and specialized quality-control testing; romidepsin's bicyclic structure is especially challenging. Branded list prices remain high, though biosimilars for bortezomib and lanreotide have entered the market. For patients, access is typically through specialty oncology pharmacies rather than retail channels — reflecting the controlled, clinician-administered nature of the class.